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A B S T R A C T
Purpose: To investigate whether it is better to use blood beta-hydroxybutyrate (BHB) or urinary ketones
to monitor ketogenic diet (KD).
Method: In 33 patients on KD we measured ketosis in two different ways. At the 3-monthly visits to the
clinic we measured BHB in capillary blood obtained by ﬁnger-prick and the level of ketones in the urine
using a urine dipstick. If the patient was able to collect urine, the urinary ketones were also measured
every day at home. We compared the degree of ketosis with seizure reduction.
Results: BHBmeasured during the 3-monthly visits correlated with seizure reduction at 3 and 6 months
(p = 0.037 and 0.019, respectively). Urinary ketones measured at the same time did not correlate at any
visit. The averaged values of the daily measured ketones in the urine did not correlate either.
Conclusions: BHB correlates better with seizure reduction than do ketones in urine. It is, therefore, better
to use BHB to monitor KD even if BHB is measured less frequently than urinary ketones.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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It is a bizarre fact that the intake of large amounts of fat can,
under certain circumstances, improve health. The ketogenic diet
(KD) is an example of a health-improving, high-fat diet applied in
cases of epilepsy. Close monitoring is essential. Several monitoring
methods exist, each with its own short-comings.
The KD is used in children with refractory epilepsy; the
application in adults is still experimental. The diet consists mainly
of fats, a sufﬁcient quantity of protein and a small amount of
carbohydrate. From former studies, it is known that the diet is
effective in a third to a half of the patients.1–3
The goal of KD is to reduce seizure frequency and seizure
severity. For a long time it was thought that this effect was
primarily due to a rise in the level of ketones which are formed by
the breakdown of the large amount of fat in the diet. Fat is
consumed in the form of triglycerides which are broken down to
fatty acids. In the mitochondria, these fatty acids are degraded by
beta-oxidation to acetyl-CoA. Normally acetyl-CoA is used in the* Corresponding author at: Epilepsy Centre Kempenhaeghe, Department of
Neurology, PO Box 61, 5590 ABHeeze, The Netherlands. Tel.: +31 40 2279 263;
fax: +31 (0)40 2265691.
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doi:10.1016/j.seizure.2009.10.009Krebs cycle to produce energy (ATP)which requires the presence of
oxaloacetate. During KD the amount of acetyl-CoA exceeds the
supply of oxaloacetate, and the resulting acetyl-CoA excess is
diverted to an alternative pathway in the mitochondria which
forms acetoacetic acid (AcAc), BHB and acetone, known collectively
as ketone bodies. These can be used by the brain as a formof energy
instead of glucose. See Fig. 1.4
In clinical practise, ketosis is measured in two different ways:
BHB is measured in blood obtained by ﬁnger-prick and the level of
ketones (mainly AcAc and a small amount of acetone) can be
assessed in the urine. BHB in blood seems to correlate better with
the amount of ketones in the brain.15 Clinically, ketosis in the urine
is usually used to monitor the diet,16–18 probably as this is less
invasive.
The current view is that ketosis achieves seizure reduction.
Whether this is due to a direct inhibiting action of ketones is not
clear. Acetone and acetoacetate have been found to inhibit seizures
in animal studies.5,6 On the other hand, beta-hydroxybutyrate
(BHB) does not seem to have an anti-convulsive capability5 and
none of the ketones have an inﬂuence on synaptic transmission.7 In
relating BHB to seizure reduction, some researchers found that a
certain amount of BHB was needed for efﬁcacy,8–11 but others
found no relationship.12–14
We investigated whether ketosis correlates with seizure
reduction in our population. In order to establish the preferredvier Ltd. All rights reserved.
Fig. 1. Ketone formation. Ketones are formed when acetyl-CoA is not able to enter
the Krebs Cycle.
Table 1
Characteristics of the study group.
Age at start of diet in years, mean
(min–max value)
16.3 (1.3–40.7)
<18 years, n (%) 19 (58)
Male, n (%) 18 (55)
Debut epilepsy (years),
mean (min–max value)
3.7 (0.0–18.0)
Generalised seizures, n (%) 17 (52)
Duration (years), mean (min–max value) 12.5 (1.3–39.3)
Amount of AED used before start of KD,
mean (min–max value)
7.9 (4–14)
IQ No retardation: 9
Mild retardation: 5
Moderate retardation: 8
Severe retardation: 11
Diet type MCT: 21
Classic: 5
MCT/classic: 5
Atkins: 2
Table 2
Seizure reduction related to BHB concentration.
Reduction BHBa 3 month (SD) n BHBa 6 month (SD) n
No efﬁcacy 1.10 (1.19) 17 0.85 (0.99) 10
<50% reduction 1.05 (0.65) 11 1.75 (2.44) 5
>50% reduction 3.0 (0.65) 5 3.5 (2.14) 5
Seizure-free –0 0.3 1
Spearman rank R=0.37, p=0.02 R=0.50, p=0.01
At 6 months, 1 BHB measurement is missing.
a BHB in mmol/L.
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urine.
2. Method
2.1. Patients
This studywas carried out in Kempenhaeghe, a tertiary epilepsy
center in the Netherlands. Since 2005, 33 patients with therapy-
resistant epilepsy, aged between 1 and 40 years, have been
included. Patients were excluded if there were medical contra-
indications (e.g. fatty acid oxidation disorders, diabetes, prolonged
QT syndrome, hypercholesterolemia, liver kidney or pancreas
disease) or the expectation that compliance with the diet was not
possible because of behavioural ormotivational problems. Patients
were excluded if they quit the diet within 6 weeks or when the
seizure diaries, required to calculate efﬁcacy, were notmaintained.
2.2. Study design
Patients were admitted to the hospital for a period of 2weeks to
introduce the diet which was administered as described in the
Dutch guideline for the ketogenic diet.19 This guideline does not
include a fasting period prior to introduction. Usually theMCT-diet
was given. If the heath insurance did not refund the cost of diet
products or if tube feeding was administered, the classic diet was
initiated or, in adults only, the Atkins diet. In some patients
changes were made in the MCT-diet, because of side-effects and
other problems encountered during its introduction. Such changes
includedmixing theMCT and the classic diet. All patients were put
on the diet by the same dietician according to the protocol.
Seizure frequency was obtained from the diaries. A 3-month
baseline was established before embarking on the diet. Reduction
was calculated by comparing the number of seizures before and
after starting the diet, the starting point being deﬁned as the ﬁrst
change made in the normal diet. In cases with more than 50%
reduction, the diet was considered effective. We did not
distinguish between the various types of seizures.
2.3. Ketosis
At every 3-month visit, ketosis was measured in an early-
morning urine sample and in a blood sample taken between 8.00
and 12.00. Ketosis in urine was measured using a urine dipstick,
which reacts mainly with AcAc and partially with the volatile
acetone. It does not cross-react with BHB. The dipstick measures
ketosis semi-quantitatively, giving values of 0 to 4+ which are
related to an amount of 0 to >16 mmol/L. BHB was measured at
every visit in capillary blood obtained by a ﬁnger-prick using a
MediSense Precision Xtra. The sample is applied to the electro-
chemical test strip producing an electronic current, which can be
measured. It has a range of 0–8 mmol/l. We tried to achieve a
ketosis of 3+ to 4+ (8–16 mmol/L) in urine and a BHB concentration
of 2–4 mmol/L in blood.
At home, ketosis was measured on a daily basis by urine
dipstick. Values were recorded and brought along to the out-
patient visits every 3 months.2.4. Statistics
Applying the SPSS programme, we related blood BHB and
urinary ketones to seizure reduction using the Spearman rank
correlation test. We also correlated the semi-quantitative average
of ketones in the urine to the seizure reduction whenmore than 10
samples in 3 months were available. Based on a pilot study of 6
measurements, we estimated a correlation between ketone body
assessment in the urine and BHB in blood of 0.7. To exclude values
of Pearson’s correlation coefﬁcient of<0.4with a power of 80% and
a signiﬁcance level of 0.05 one-sided, 33 patients were needed.
Correlations with p < 0.05 were considered signiﬁcant.
3. Results
The present study included 33 patients whose characteristics
can be found in Table 1.
Three months after the start of the study, all patients were still
on the diet. At 6, 9 and 12 months there were respectively 22, 11
and 10 patients on the diet. At 3 and 6months, respectively 5 and 6
patients showed a seizure reduction of more than 50%. Of the 33
patients included, 8 achieved a seizure reduction of more than 50%
(at 3 or 6 months) which means that in this study KDwas effective
in 24% of the patients. Once the diet became effective no relapse
was seen in any of the patients.
When we correlated the ketosis measured at the visits with
seizure reduction, we found a signiﬁcant correlation for BHB in the
capillary blood at 3 and 6 months (p = 0.02 and 0.01), see Table 2,
Figs. 2 and3. Interestingly, theonepatient in this studywho reached
complete seizure reduction on KD had a BHB comparable to those
without seizure improvements. Therewasnocorrelation foundwith
ketones measured in the urine during these visits (p = 0.44 at 3
months and p = 0.37 at 6 months). At 9 and 12 months, we did not
ﬁnd any signiﬁcance for either test (data not shown).
Normally the diet is not monitored on the basis of only one
sample of urine ketosis; the ketosismeasured at home is also taken
Fig. 2. BHB concentration related to reduction at 3 months.
Fig. 3. BHB concentration related to reduction at 6 months.
Fig. 4. Ketones in urine (average) related to reduction at 3 months. Spearman rank:
R = 0.10, p = 0.32.
Fig. 5. Ketones in urine (average) related to reduction at 6 months. Spearman rank:
R = 0.09, p = 0.36.
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the average of all the values measured by the patients at home. 25
patients at 3months and 17 patients at 6months hadmeasured the
ketosis frequently. But the average of several measurements of
ketones in the urine did not correlate with the reduction at any
time, Figs. 4 and 5.
4. Discussion
In this study we show that BHB correlates better with seizure
reduction than urinary ketones. Even the average ketosis of several
urine samples, measured at home, did not correlate with seizure
reduction. BHB is, therefore, more useful in patients on KD. Gilbert
et al. came to the same conclusion as did Likhodii et al. when
studying KD in rats.8,11 Clinically, the urine dipstick is used more
often to monitor KD, but our study tends to support the use of BHB
rather than urine. A ketosis found in the urine only indicates
compliance but it is not a value to aim for in terms of efﬁcacy.
Furthermore, fewer measurements of BHB might be required to
evaluate the degree of ketosis, as only one value of BHB in 3monthsalready correlates with seizure reduction. We were not able to
collect BHB and urine samples in all 33 patients. Some patients
were not able to measure ketosis in the urine every day because of
incontinence. There is no reason to consider the ketosis would be
different in the excluded patients. Nor were we able to measure
BHB at a ﬁxed time due to the fact that most patients using the KD
have complex epileptic disorders and are often mentally retarded.
Allmeasurementswere, however, carried out in themorning. Since
the amount of BHB varies during the morning, this might have
inﬂuenced the level, but as this is the case in both non-responders
and in responders, bias may be less likely to have occurred.
The correlation with BHB was not found at 9 and 12 months,
possibly due to the small number of patients in the study at that
time, but Gilbert et al. came to the same conclusion.8 We can only
speculate that this indicates that BHB is not the ultimate parameter
for monitoring the KD—also, the only patient who became seizure-
free had a low level of BHB. But there is as yet no better parameter
available.
The efﬁcacy in this study was 24%, which is low compared to
other KD studies.1–3 Bias may be present because caregivers may
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of the KD as compared to the preceding period (baseline period). In
addition, adultswere also included in this study, and efﬁcacymight
be lower in adults compared to children.
We did not stratify for the form of KD (e.g. MCT, classical,
Atkins), therefore, we do not know whether ketosis is less well
correlated to seizure reduction in one diet compared to another.
However, since ketosis was measured and the results were used in
the same way in all KD, conclusions drawn in this paper are
applicable to all KD.
We did not stratify for the different age groups either and
therefore do not knowwhether ketosis in adults relates differently
to seizure control compared to ketosis in children. This is due to the
limited number of patients included in this study and thewide age-
range. Clinicians do, however, try to reach the same level of ketosis
in adults as they do in children and therefore this difference is
probably not that important for the aim of the study.
In the present study we showed that infrequent BHB assess-
ment can be used instead of daily ketone assessments in urine to
monitor KD. Under certain circumstances, it shows even better
correlation with seizure reduction.
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